JPMorgan Chase & Co. Sells 176,780 Shares of Certara, Inc. (NASDAQ:CERT)

JPMorgan Chase & Co. cut its position in shares of Certara, Inc. (NASDAQ:CERT) by 4.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,872,515 shares of the company’s stock after selling 176,780 shares during the quarter. JPMorgan Chase & Co.’s holdings in Certara were worth $45,347,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in CERT. 272 Capital LP acquired a new stake in shares of Certara during the 3rd quarter worth approximately $586,000. Barclays PLC raised its position in Certara by 198.3% in the 3rd quarter. Barclays PLC now owns 70,525 shares of the company’s stock valued at $825,000 after buying an additional 46,880 shares during the last quarter. Jane Street Group LLC boosted its holdings in Certara by 2.6% during the third quarter. Jane Street Group LLC now owns 147,393 shares of the company’s stock worth $1,726,000 after purchasing an additional 3,732 shares during the last quarter. State Street Corp grew its position in Certara by 3.4% in the 3rd quarter. State Street Corp now owns 3,679,699 shares of the company’s stock worth $43,089,000 after purchasing an additional 122,411 shares in the last quarter. Finally, Petrus Trust Company LTA purchased a new stake in Certara in the 3rd quarter valued at about $994,000. 73.96% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

CERT has been the subject of a number of research analyst reports. UBS Group upgraded shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 price objective for the company in a report on Friday, September 27th. Barclays reduced their target price on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a research report on Thursday, November 7th. Finally, Robert W. Baird lowered their price target on shares of Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a report on Tuesday, November 5th. Six equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, Certara presently has a consensus rating of “Hold” and an average target price of $15.92.

Certara Price Performance

Shares of NASDAQ:CERT opened at $11.21 on Monday. The stock has a market cap of $1.80 billion, a P/E ratio of -56.05, a P/E/G ratio of 5.86 and a beta of 1.53. Certara, Inc. has a 12 month low of $9.41 and a 12 month high of $19.87. The company has a 50 day moving average of $10.76 and a 200 day moving average of $12.08. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.02. The firm had revenue of $94.80 million for the quarter, compared to analyst estimates of $95.51 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The business’s revenue for the quarter was up 10.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.06 EPS. As a group, sell-side analysts forecast that Certara, Inc. will post 0.28 EPS for the current fiscal year.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.